KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Short-term Investments (2018 - 2023)

Esperion Therapeutics' Short-term Investments history spans 6 years, with the latest figure at $17.4 million for Q1 2023.

  • For Q1 2023, Short-term Investments fell 74.42% year-over-year to $17.4 million; the TTM value through Mar 2023 reached $17.4 million, down 74.42%, while the annual FY2022 figure was $42.1 million, 16.56% down from the prior year.
  • Short-term Investments reached $17.4 million in Q1 2023 per ESPR's latest filing, down from $42.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $68.1 million in Q1 2022 to a low of $2.2 million in Q2 2020.
  • Average Short-term Investments over 5 years is $35.7 million, with a median of $33.3 million recorded in 2019.
  • Peak YoY movement for Short-term Investments: crashed 91.64% in 2020, then dropped 16.56% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $34.7 million in 2019, then crashed by 93.52% to $2.2 million in 2020, then skyrocketed by 2144.82% to $50.4 million in 2021, then decreased by 16.56% to $42.1 million in 2022, then plummeted by 58.59% to $17.4 million in 2023.
  • Per Business Quant, the three most recent readings for ESPR's Short-term Investments are $17.4 million (Q1 2023), $42.1 million (Q4 2022), and $29.9 million (Q3 2022).